Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 14NIH 4OTHER_GOV 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Thyroid Neoplasms 1Pheochromocytoma 1Paraganglioma 1Neuroendocrine Tumors 1Differentiated Thyroid Cancer 1

Interventions

lenvatinib 9vandetanib 5pembrolizumab 4Sorafenib 4selpercatinib 3Thyrotropin Alfa 3trametinib 2fosbretabulin 2combretastatin 2cabozantinib 2belinostat 2Paclitaxel 2Gemcitabine 2Fluorouracil 2Cetuximab 2Carboplatin 2Axitinib 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1tipifarnib 1surufatinib 1repotrectinib 1pralsetinib 1naporafenib 1motesanib diphosphate 1methyl N-acetylsibirosaminide 1larotrectinib 1irofulven 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Neoplasms × Iodine-131 × Clear all
NCT00196729 2015-03-18

Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I Administration

Sanofi

Phase 3 Completed
63 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡